This is the definitive drug development forum for research teams to investigate how to modulate the cGAS-STING and Toll-like receptor (7/8/9) pathways both as monotherapies and as
Servier’s vorasidenib has shown efficacy in the treatment of low-grade glioma – a notoriously hard-to-treat form of brain cancer – although safety data has taken some of t
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas